About us

Aptarion Biotech develops new treatments for life-threatening diseases. Aptarion’s lead drug candidate AON-D21 is currently being tested in a Phase 2 clinical trial in 100 patients diagnosed with severe community-acquired pneumonia.

Aptarion leverages the unique properties of mirror-image (L-)aptamers. L‑Aptamers are single-stranded L-RNA or L-DNA molecules combining high target affinity, specificity and biostability with the ease of a scalable chemical production process.

Aptarion is headquartered in Berlin, Germany.